IP Library › Granted Patent US 11,186,641
Granted Patent B2
US 11,186,641 · App. 16/085,126 · Granted Nov 30, 2021

Fusion proteins targeting tumour associated macrophages for treating cancer

Inventor: Anders Tveita (Oslo, NO)
Assignee: OSLO UNIVERSITETSSYKEHUS HF
C07K16/2851A61K38/20A61P35/00C07K14/7155C07K16/28C07K16/2896C07K16/40C12N15/62A61K38/00A61K2039/505A61K2039/572C07K2317/22C07K2317/569C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,186,641
App. No.
16/085,126
Granted
Nov 30, 2021
Kind
B2
Abstract

The present invention relates to cancer immunotherapy. In particular, provided herein are fusion proteins for targeting tumor associated macrophages with immunostimulatory agents.

Claims (2)

1. A fusion protein comprising an IL-15 polypeptide fused to an antigen binding protein wherein said fusion protein is encoded by the nucleic acid sequence SEQ ID NO: 1.

2. The fusion protein of claim 1 , wherein said antigen binding protein specifically binds to said CD206.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2018
From: TVEITA, ANDERS
To: OSLO UNIVERSITETSSYKEHUS HF
Reel/Frame 047476/0752 →
Continuity (2)
Provisional Application 62309704 · Mar 17, 2016
Related Publication 20190023795A1 · Jan 24, 2019
Cited By (1)
US 12,195,544